- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03197662
Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
This study is a phase 2 randomized double blind 8-week treatment trial of intranasal OXT vs. placebo in 50 subjects aged 5 to 17 years with PWS in order to assess IN-OXT's affect on measurements of (1) eating behaviors (2) repetitive behaviors (3) weight and body composition (4) quality of life (5) salivary OXT and hormone levels (including ghrelin, pancreatic polypeptide, peptide YY, GLP-1, insulin, glucagon, testosterone, and estrogen). If superior to placebo, this data will add to the current knowledge that OXT is an effective treatment for hyperphagia as well as other symptoms of PWS.
Funding Source- FDA OOPD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder caused by lack of expression of paternally derived imprinted material on chromosome 15q11-q13. PWS is characterized by mild to moderate intellectual disabilities, repetitive/compulsive behaviors and rigidity, social cognition deficits and severe hypotonia at birth, followed by the onset of hyperphagia later in life. Obesity is responsible for the majority of the morbidity and mortality associated with PWS, and compulsive eating behaviors are most responsible for diminishing the quality of life for caregivers and family members. Oxytocin has been implicated in the pathophysiology of PWS and there have been small studies of intranasal oxytocin (IN-OXT) in this population. To date, however, studies have not been adequately powered to detect significance in target symptoms of hyperphagia and associated symptoms of individuals with PWS. The primary goal of this study is to examine the safety and efficacy of IN-OXT on hyperphagia, as measured by the Hyperphagia Questionnaire-Clinical Trails, from baseline to week 8. Currently, there are no effective treatments available to manage hyperphagia in patients with PWS.
STUDY DESIGN: This is an 8-week double-blind, randomized study in 50 children with PWS aged 5-17. Participation involves 2 in-person visits to our program and 5 remote visits. Travel expenses will be reimbursed to participating families.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Bonnie Taylor, PhD
- Phone Number: 718-839-7530
- Email: botaylor@montefiore.org
Study Locations
-
-
New York
-
Bronx, New York, United States, 10461
- Recruiting
- Montefiore Medical Center, Albert Einstein College of Medicine
-
Contact:
- Bonnie Taylor, PhD
- Phone Number: 718-839-7530
- Email: botaylor@montefiore.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female pediatric outpatients aged 5 to 17 years
- Must be in PWS nutritional phase 2b or 3 as determined by PI
- Must be on growth hormone treatment and have been receiving stable doses of growth hormone treatment for at least 3 months prior to screening date. Treatment cannot have been interrupted for more than one week within 3 months of screening.
- Diagnosis of PWS confirmed by patient medical records.
- A score of at least moderate severity on the Hyperphagia Questionnaire for Clinical Trials at both screening and baseline visits.
- Stable dosages of hormone treatments (including testosterone and estrogen supplements) for 4 weeks prior to randomization and for the duration of the study.
- Stable dosages of metabolic treatments that could affect appetite (including metformin) for 4 weeks prior to randomization and for the duration of the study.
- Physical exam and laboratory results that are within the normal range for individuals with PWS.
- Presence of a parent/caregiver/guardian that is able to consent for their participation and complete assessments regarding the child's development and behavior change throughout the study.
Exclusion Criteria:
- Exposure to any investigational agent in the 30 days prior to randomization.
- Child not receiving growth hormone treatment
- Children weighing less than 40 lbs
- Children with unstable Type 2 Diabetes confirmed by Hemoglobin A1C levels at screening
- Children with unstable medical co-morbidities at baseline.
- Children with active upper respiratory infections at screening.
- A primary psychiatric diagnosis other than ASD, including bipolar disorder, psychosis, schizophrenia, PTSD or MDD. These patients will be excluded due to potential confounding results.
- Pregnant or lactating patients or patients who will not agree to use a double barrier method of contraception. IN-OXT has not been studied in pregnant or lactating women.
- Females using an estrogen-based contraceptive. As an alternative to an estrogen based contraceptive, subjects will be counseled to use progesterone-based contraceptives; cervical cap; cervical sponges; or spermicidal foam in combination with a condom. Subjects will need to use a double barrier method to be in the study.
- A medical condition that might interfere with the conduct of the study, confound interpretation of study results or endanger the subject's well-being.
- A known diagnosis of Rett's Syndrome of Childhood Disintegrative Disorder or marked sensory impairment such as deafness or blindness.
- Subjects who have changes in allied health therapies, behavioral or educational interventions within four weeks prior to randomization other than those associated with school holidays.
- Subjects who have had changes in medications or medication doses of risperidone, aripiprazole, other antipsychotic medications, clonidine, guanfacine, stimulants or anti-convulsants within four weeks of randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Intranasal Oxytocin (IN-OXT)
Syntocinon (synthetic oxytocin) will be used in this protocol.
Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
|
Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each).
If needed, treatment will be titrated due to side effects or non-response.
Other Names:
|
Placebo Comparator: Placebo Comparator: Matched Placebo
Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
|
Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each).
If needed, treatment will be titrated due to side effects or non-response.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hyperphagia Questionnaire for Clinical Trials
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Assesses Eating Behaviors and Hyperphagia in PWS.
Repeated Measures Analysis.
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Repetitive Behavior Scale Revised (RBS-R)
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in Repetitive Behavior Scale (RBS-R) from baseline to endpoint
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
BMI
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in BMI from baseline to endpoint
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Body Composition
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in Body Composition (measured via bioelectrical impedance analysis) from baseline to endpoint
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
World Health Organization Quality of Life Questionnaire (WHOQOL)
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in World Health Organization Quality of Life Questionnaire from baseline to endpoint
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Aberrant Behavior Checklist
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in Aberrant Behavior Checklist (ABC) from baseline to Endpoint.
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Salivary Oxytocin Concentration
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in Salivary Oxytocin Concentration from baseline to endpoint
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Caregiver Strain Questionnaire
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in Caregiver Strain Questionnaire from baseline to endpoint
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Montefiore-Einstein Rigidity Scale-Revised PWS (MERS-PWS):
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in three domains of rigid behavior from baseline to endpoint
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Automated, Self-Administered, 24 Hour Recall Diary System
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in ASA 24: Automated, Self-Administered, 24 Hour Recall Diary System from baseline to endpoint
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Relationship between weight-based dosing and hyperphagia treatment response
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
|
Hormone levels (Ghrelin, pancreatic polypeptide, peptide YY, GLP-1, insulin, glucagon, testosterone, and estrogen)
Time Frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Change in hormone levels (ghrelin, pancreatic polypeptide, peptide YY, GLP-1, insulin, glucagon, testosterone, and estrogen) from baseline to endpoint.
|
From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eric Hollander, MD, Albert Einstein College of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Congenital Abnormalities
- Signs and Symptoms, Digestive
- Overnutrition
- Nutrition Disorders
- Genetic Diseases, Inborn
- Intellectual Disability
- Abnormalities, Multiple
- Chromosome Disorders
- Obesity
- Syndrome
- Prader-Willi Syndrome
- Hyperphagia
- Physiological Effects of Drugs
- Reproductive Control Agents
- Oxytocics
- Oxytocin
Other Study ID Numbers
- 2017-8076
- FD-R-05106-01 (Other Grant/Funding Number: FDA-OOPD)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperphagia
-
Laval UniversityUnknown
-
Rennes University HospitalInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'EnvironnementRecruiting
-
University of MichiganCompleted
-
University of LeedsAlmond Board of CaliforniaCompletedHyperphagia | Lack of Satiety
-
University Hospital, LinkoepingCompletedHealthy | Hyper-AlimentationSweden
-
Northwestern UniversityUniversity of California, San Diego; University of California, Los Angeles; University... and other collaboratorsCompleted
-
St. Luke's-Roosevelt Hospital CenterGlaxoSmithKlineTerminated
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Pennington Biomedical Research CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of MinnesotaRecruitingAcute OvereatingUnited States
Clinical Trials on Intranasal Oxytocin (IN-OXT)
-
Montefiore Medical CenterFoundation for Prader-Willi ResearchCompletedHyperphagia | Prader-Willi SyndromeUnited States
-
University of Electronic Science and Technology...Completed
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
University Hospital, ToulouseCompletedPrader-Willi SyndromeFrance
-
Massachusetts General HospitalUnited States Department of DefenseRecruitingAutism Spectrum Disorder | Bone HealthUnited States
-
Icahn School of Medicine at Mount SinaiRecruitingBorderline Personality DisorderUnited States
-
MacDonald, Kai, M.D.CompletedAnxiety | BehaviorUnited States
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
University of Electronic Science and Technology...Recruiting
-
Maria de las Mercedes Perez RodriguezJames J. Peters Veterans Affairs Medical Center; VISN 3 Mental Illness Research...TerminatedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder | Autism Spectrum Disorder | Borderline Personality Disorder | Schizotypal Personality Disorder | SPD | BPDUnited States